Private Advisor Group LLC Acquires 95,960 Shares of Johnson & Johnson $JNJ

Private Advisor Group LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 34.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 373,648 shares of the company’s stock after purchasing an additional 95,960 shares during the quarter. Private Advisor Group LLC’s holdings in Johnson & Johnson were worth $98,920,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of JNJ. Tyche Wealth Partners LLC raised its position in shares of Johnson & Johnson by 41.2% during the 3rd quarter. Tyche Wealth Partners LLC now owns 31,618 shares of the company’s stock worth $8,371,000 after purchasing an additional 9,219 shares during the last quarter. Taylor Hoffman Capital Management LLC boosted its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Taylor Hoffman Capital Management LLC now owns 31,107 shares of the company’s stock worth $8,235,000 after buying an additional 135 shares during the last quarter. Ieq Capital LLC boosted its holdings in Johnson & Johnson by 3.7% in the 3rd quarter. Ieq Capital LLC now owns 317,488 shares of the company’s stock worth $84,052,000 after buying an additional 11,343 shares during the last quarter. Focus Advisor Solutions LLC increased its stake in Johnson & Johnson by 48.6% during the 3rd quarter. Focus Advisor Solutions LLC now owns 70,070 shares of the company’s stock worth $18,551,000 after buying an additional 22,901 shares in the last quarter. Finally, BHK Investment Advisors LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at approximately $203,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JNJ shares. Wells Fargo & Company raised their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a report on Tuesday, October 20th. Guggenheim reissued a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 7th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Read Our Latest Research Report on JNJ

Johnson & Johnson Stock Down 2.1%

Shares of NYSE:JNJ opened at $272.75 on Thursday. The company has a market capitalization of $656.58 billion, a price-to-earnings ratio of 41.33, a PEG ratio of 2.75 and a beta of 0.22. Johnson & Johnson has a 12-month low of $199.38 and a 12-month high of $290.25. The business has a 50-day moving average price of $267.42 and a 200 day moving average price of $250.61. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Key Stories Impacting Johnson & Johnson

Investors following JNJ have been watching these stories:

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 13,072 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.